INTRODUCTION
============

In sub-Saharan Africa, the transmission of Human Immunodeficiency Virus (HIV-1) occurs mostly through heterosexual contact and the progression to Acquired Immunodeficiency Syndrome (AIDS) and premature death is the reality for people in most poor areas with limited access to Antiretroviral Therapy (ART) \[[@R1]-[@R3]\]. HIV disease progresses from an asymptomatic period of variable duration, through mild symptoms, to severe disease characteristic of cellular immunodeficiency \[[@R1]\].

Human Immunodeficiency Virus clinical presentation is known to be complex since AIDS was described in 1981\[[@R2],[@R3]\]. HIV can manifest in a variety of ways depending on the organs affected and concurrent infections prevalent in the area. The initial clinical presentation may mimic symptoms of common endemic diseases in that particular region \[[@R4],[@R5]\] However, the severity of manifestation depends on the infected individual's baseline health status. The most significant early manifestation of HIV infection in Africa was marked by slim disease (diarrhoea and wasting); tuberculosis; variety of Opportunistic Infections (OI); weight loss, fever; and dermatological symptoms \[[@R2],[@R5],[@R6]\]. With the exception of tuberculosis which continues to increase, other AIDS related diseases are declining gradually due to the widespread use of OI drugs.

World Health Organization (WHO) has established a four stage clinical classification system determined by the presence of Opportunistic Infections and other HIV related conditions \[[@R7]\]*.* This classification tried to incorporate most of the AIDS-defining illnesses occurring in all regions of the world making a global tool for HIV/AIDS patients care and treatment. It has been a very useful tool in Sub Saharan Africa at the introduction of antiretroviral drugs and establishment of HIV/AIDS treatment cohorts \[[@R8]\]. It helped to capture rapid deteriorating patients and initiation of ART in settings with limited diagnostic resources and less trained clinicians.

Antiretroviral drugs are widely available nowadays and continue to be scaled up in remote rural areas of sub Saharan Africa \[[@R9],[@R10]\]. The aim of rapid scale up is to reach more people living with HIV and AIDS who cannot easily access ART services in urban hospitals. The main challenges to this plausible strategy include availability of qualified health workers and laboratory services to ensure quality care and the monitoring of drug use \[[@R11]-[@R13]\]. In addition, most patients including HIV-infected patients in Sub Saharan Africa present late for hospital care and treatment when the disease has advanced \[[@R13]-[@R15]\]. By then initial AIDS signs and symptoms might have been treated empirically through self medication or use of herbal medicines. Such remedial actions usually obscure important AIDS clinical features and make it difficult for the attending clinician to solicit signs and symptoms to properly stage the patient.

It is evident that HIV/AIDS patients' management in Sub Saharan Africa continues to be guided primarily by clinical staging \[[@R8],[@R16],[@R17]\] owing to the insufficient availability and/or frequent breakdowns of CD4 cells count machines, shortage of qualified medical personnel and laboratory reagents and other logistic issues impair \[[@R18]\]. On the other hand WHO clinical staging depends on a patient presenting signs and symptoms; knowledge and skills of the health care worker to make a definitive staging \[[@R8],[@R17],[@R19]\]. Furthermore, WHO clinical staging is less sensitive in identifying patients with CD4 cell counts between 200 -350 cells per µL \[[@R4],[@R20]\]*.* Therefore, it fails to identify some patients in need of ART.

Taking into considerations the complexities of HIV clinical manifestation in our setting which often does not match WHO clinical staging. Clinicians in lower health facilities, who are expected to attend to HIV patients in their local settings, need simplified and easy to use clinical staging guidelines developed by utilizing site specific data and clinical experiences. This approach could effectively support management of HIV/AIDS patients in ART cohorts based on site specific experiences. Moreover, the broader availability of ART as well as new approaches to deal with opportunistic infections call for a review of the clinical presentations seen within care and treatment programs in different settings. To date, no studies have proposed simplified HIV/AIDS clinical staging based on local experience. With the inspiration of WHO validated HIV/AIDS clinical definition, our study aimed at developing simplified HIV/AIDS clinical staging system based on data generated locally from peri-urban and rural health facilities to allow more effective patient management and ART cohorts at peripheral level in the absence of CD4 counts.

METHODS
=======

Setting and Study Participants
------------------------------

The study was conducted at Tumbi Regional Hospital and Chalinze Health Centre in Pwani Region, Eastern Tanzania between April and December 2008. Tumbi Regional Hospital is located 40 km from Dar es Salaam, the commercial capital of Tanzania. The hospital has a bed capacity of 200 beds and serves as a regional referral Hospital. Chalinze Health Centre is located 70 km from Tumbi Hospital at the junction of the main upcountry highways with HIV prevalence of 15%, while Pwani Region prevalence was 7%. Both health facilities provide services to a mixture of patients from urban and rural villages. Most residents of Chalinze reside in rural villages and generate income from farming and trading of different types of goods.

Tumbi Hospital runs two separate HIV/AIDS clinics for adults and children. At the time of initiation of this study in April 2008, Tumbi Hospital and Chalinze Health Centre had enrolled a total of 3851 and 450 patients to care and treatment, respectively.

We recruited HIV-infected adult patients (age ≥15 years) coming for the first time to register for care and treatment services. The inclusion criteria included; permanent residence to the health facility catchments area; no prior use of ARVs and or co-trimoxazole prophylaxis. A total of 360 female and male patients consented to participate in the study as depicted in the flow chart (Fig. **[1](#F1){ref-type="fig"}**). Recruitment of study participants lasted for 3 months.

Data Collection
---------------

Each consenting patient was clinically examined in the standard way that involved a detailed history, physical examination and laboratory tests. Additional laboratory tests depended on the suspected diagnosis. Patients' socio-demographic characteristics and clinical information were recorded in a structured report form in addition to routine patient case report forms.

Laboratory Procedures
---------------------

Blood, sputum, urine and stool samples were collected and analyzed. Blood samples were analyzed for CD4 cell counts, HIV-1 P24 plasma ELISA assay, haemoglobin, liver and renal function tests. Blood was collected in EDTA tubes for enumeration of CD4 cells by using FACS count (BD Biosciences, California, USA). Biochemistry and haematological parameters were analyzed using Biochemical analyzer (Italy) and haematological analyzer (Pentra 80, France) respectively. Thick blood smears were Giemsa stained and microscopically examined for Malaria parasitaemia \[[@R21]\]. Sputum specimens were stained using Ziehl-Neelsen technique and examined for mycobacterium tuberculosis \[[@R22]\].

Stool samples were fixed using sodium acetate-acetic acid-formalin (SAF) solution and microscopically examined for intestinal parasites. Part of freshly passed stool was inoculated and cultured in Xylose Lysine Deoxycholate Agar (XLD) media for Salmonella and Shigella species. A direct microscopic examination was performed on urine samples. This paper focuses on CD4 cell counts results in comparison to the WHO clinical staging.

Data Analysis
-------------

All data was entered into Microsoft ^®^Access, and analyzed using Stata Intercooled version 9.

Each clinical symptom or sign was coded and counted individually to estimate the frequency of occurrences from every patient. About 140 different signs and symptoms were recorded. Then the frequencies were used to estimate the proportion of patients with that particular sign or symptom. Only signs and symptoms with high frequencies were used in this analysis.

We attempted to form two simplified management groups of patients based on either CD4 counts categories or WHO clinical stages. With respect to WHO clinical staging; group one (severe immune suppression) is formed by patients with clinical stages III/IV and group two (moderate immune suppression) is formed by patients with clinical stages I/II. Similarly, when using CD4 cell counts severe immune suppression was defined by patients with CD4≤200 cells per µL whilst moderate immune suppression is formed by patients with CD4\>200 cells per µL.

We then determined sensitivity, specificity, positive and negative predictive values using CD4 cells count level as the "gold standard". Symptoms or signs individually and in combinations were used to predict severe disease. Only symptoms which had high frequency and troubled the patient for more than two weeks were used.

Ethical Approval
----------------

The study received scientific and ethical approval from the Muhimbili University of Health and Allied Sciences Research Ethics Review Board. Permission was obtained from Region, District and local site authorities. Written informed consent or witnessed verbal consent for participants unable to read or write was obtained from each patient in Kiswahili.

RESULTS
=======

During the study period 421 HIV-infected patients aged 15 to 80 years were recruited to participate in the study, 341(81.0%) and 80(19.0%) were from Tumbi hospital and Chalinze health centre, respectively. Sixty one (14.5%) patients declined to participate due to various reasons (Fig. **[1](#F1){ref-type="fig"}**). In total 360(85.5%) patients were consented, complete data for analysis was recorded from 331 (78.6%) patients. Twenty nine patients were excluded from the final analysis due to incomplete data, i.e. doubtful CD4 counts results or names, age and sex not corresponding to clinical information. Patients rejected to participate in the study and those excluded from analysis had similar social and demographic characteristics to those finally analyzed.

Socio-Demographic and Clinical Characteristics
----------------------------------------------

Table **[1](#T1){ref-type="table"}** summarizes demographic and clinical characteristics of the participants. There were 191(57.7%) patients in the study with CD4+ T-lymphocytes count of less than 200 cells per µL. The median age was comparable in both groups of patients with mild and severe immunosuppression. Most patients 214(64.7%) were females, and the majority 223(67.4%) of patients resided in rural areas. Seventeen patients (8.9%) and 37(19.4%) with CD4+ T-lymphocytes below 200 cells per µL were classified with WHO clinical stages I and II, respectively. Similarly, 35(25.0%) and 25(17.9%) of patients were staged in clinical stages III and IV, respectively, had CD4+ T-lymphocytes greater than 200 cells per µL. The overall median CD4+ T-lymphocytes counts at enrolment was 158(IQR 253) cells per µL, with the lowest median (77.5 (IQR 99.5)) in patients with severe immunosuppression.

Patient's Main Presenting Symptoms and Signs at Recruitment
-----------------------------------------------------------

At presentation to the clinic weight loss of more than 5 kg was the most frequent 160(48.3%), followed by chronic cough that persisted for more than 2 weeks 135(40.8 %). Diarrhoea was less common (10.6 %) in this study population. Recurrent fever was recorded in 132(39.9%) patients; other symptoms with high frequency included headache 105(31.7 %); Peripheral neuropathy 57(17.2%) and dizziness 70(21.1%). Various types of skin diseases were recorded in 34(10.3%) patients, but Pruritic Papular Eruptions was the most common dermatological condition (Table **[2A](#T2A){ref-type="table"}**). Thirty six (11%) patients presented with genital discharge; 12(33%) of them had sexually transmitted infections. In addition to major clinical symptoms and signs; 132 (37%) patients presented with mild non-specific various clinical features. Major AIDS-defining Opportunistic Infections diagnosed in this study included: Tuberculosis (15%); *Pneumocystis carinii* Pneumonia (7%); Herpes zoster (5%); *Cryptococcus meningitis* (3%); and Kaposi's sarcoma (3%).

Performance of clinical features to predict severe immunosuppression in comparison to WHO clinical staging Tables **[2A](#T2A){ref-type="table"}**, **[2B](#T2B){ref-type="table"}** and **[2C](#T2C){ref-type="table"}** demonstrate the performance of each AIDS presenting symptom alone or in combination with other symptoms in predicting severe immunosuppression. Patients presenting with diarrhoea for more than two weeks have about double the odds ratio of being severely immunosuppressed. Diarrhoea is an important predictor of severe immunosuppression even when presenting with other symptoms (odds ratio ranging from 1.97(95%CI, 0.68-5.66) to 4.21(0.92-19.33) for two and three combination of symptoms). Chronic cough and weight loss are routinely used to classify patients in stages III and IV (WHO odds ratio of 3.28 (95%CI, 2.02-5.32), 2.49(1.58-3.95) respectively), but do not specifically predict severe immunosuppression (CD4≤200 odds ratios 1.44(95%CI, 0.92-2.25) and 1.39(95%CI, 0.89-2.16), respectively) when presented as individual symptoms. Their performance in predicting severe immunosuppression improves when presented in combination with other HIV/AIDS clinical manifestations (Tables **[2B](#T2B){ref-type="table"}** and **[2C](#T2C){ref-type="table"}**).

Headache, Dizziness and Peripheral neuropathy were among the most frequent symptoms. These symptoms appear to be highly sensitive (sensitivity 80-85%) in predicting severe immunosuppression when used as individual symptoms. Similarly, HIV/AIDS patients presenting with dizziness have about two times the odds of being staged in WHO clinical stage III/IV (WHO odds ratio=1.93(95%CI, 1.06-3.43)). But these are non- specific HIV/AIDS clinical manifestations and poorly predicted severe immuno-suppression when compared to CD4 cell counts (CD4≤200 odds ratios 0.96(95%CI, 0.60-1.54) and 1.53(95%CI, 0.88-2.65) respectively). The same symptoms when presented in combination with other symptoms such as diarrhoea the probability of predicting severe immunosuppression increases (CD4≤200 odds ratio 4.21(95%CI, 0.91-19.33) for the combination of dizziness and diarrhoea; and for weight loss, headache and diarrhoea).

Sensitivity of each one or combination of two most frequent symptoms to predict severe disease was between 71% (Skin disease) and 93% (Fungal infection); and specificity minimum 29% (combination of cough and fever) and maximum 70% (Diarrhoea). Fungal infection carried the highest sensitivity of 93% with WHO clinical stage III/IV odds ratio of 2.75(1.0-7.56). But, when compared to CD4 cell counts, the CD4≤ 200 odds ratio drops to 1.24(0.52-2.92).

The combinations of three clinical features resulted in an improved prediction of severe immune suppression. However, adding headache into a combination fever and diarrhoea increased the odds of severe immunosuppression (based on CD4 counts) from 2 to 4 folds. A similar trend is observed when added in a combination of weight loss and diarrhoea contrary to difficulty in breathing which behaved differently when added in a combination of cough and diarrhoea and or fever and diarrhoea.

DISCUSSION
==========

This study attempted to develop and validate HIV clinical staging tailored to a particular geographical and endemic area in comparison to the well established WHO-staging. The clinical profiles of about 34% of patients were unique and obscured which in turn resulted in WHO staging that was inconsistent with the CD4 cell counts. The majority of the patients presented with clinical features of weight loss (and wasting); chronic cough; and persistent fever for more than 2 weeks. These are common symptoms and signs which were described as early HIV manifestation and significantly were associated with sero-conversion in the first decades of HIV epidemic \[[@R23],[@R24]\]. We also observed a marked shift in AIDS clinical manifestation from the classical AIDS clinical manifestations \[[@R23]\] which previously was marked by profound weight loss of more than 10% body weight; chronic diarrhoea and prolonged fever for more than one month to a mixed picture of signs and symptoms \[[@R23]-[@R25]\]. Although, our patients had reported weight loss, the weight loss was limited to more than 5 kg and less than 5% (data not shown) of their initial body weight. The clinical spectrum seen among the patients in both study sites are quite representative to the overall clinical pictures of the HIV/AIDS patients in the area. The two sites are the only care and treatment centres in the whole area.

Interestingly, only 10.6% of the patients presented with chronic diarrhoea. This is a marked reduction in occurrence of diarrhoea among HIV/AIDS patients attending care and treatment clinics. Diarrhoea is well known to affect 40%-80% HIV infected persons and was also associated with high mortality rates in Sub-Saharan Africa \[[@R24],[@R26],[@R27]\]. The reduction in prevalence of diarrhoea in HIV infected people can be explained by the now broader availability of OIs drugs and co-trimoxazole without prescription.

Working at care and treatment centres, we recruited newly diagnosed HIV patients that were all included in the ART cohorts according to the Tanzania National HIV/AIDS control programme guidelines. We expected to record more pre-AIDS signs and symptoms such as generalized lymphadenopathy, Herpes zoster and mucocutaneous lesions. Instead, one third of our patients presented with minor non specific and often no symptoms. Most of these patients had CD4 cell counts less than 200 cells per µL. Herpes zoster was diagnosed in 5% of patients, most of them had CD4 cell counts below 200 cells per µL which is contrary to the common believe that Herpes zoster is a stage II disease. It is a reality in most rural, poor communities to accept a HIV test after suffering for a long time and tried on all kinds of remedies without success. During this time their CD4 cell counts progressively declined.

Most of the known common HIV related opportunistic infections were less frequent than expected in this population despite many patients having CD4 cell counts less than 200 cells per µL. It is well established that patients at this level of CD4 cell counts have high risk of AIDS opportunistic infections and AIDS related cancers \[[@R28]\]. Tuberculosis was diagnosed in only 15% of the patients despite the high frequency of chronic cough and difficulty in breathing. Patients with extra pulmonary tuberculosis and Pneumocystis carinii pneumonia could be missed due to limited respective diagnostic facilities. The diagnosis of these diseases was based on sputum and chest x-ray findings. In routine practice, tuberculosis in HIV-infected patients requires regular screening at every visit because single screening does not exclude latent infection that can flare up in the course of HIV disease progression.

Cryptococcus meningitis and Kaposi's sarcoma were diagnosed in only 3% of the patients. However, the lower rate of HIV related cancers can be justified by the small sample size of this study. Overall, the different clinical patterns and frequencies of opportunistic infections may largely be due to changed approaches in the clinical management brought forward by (i) the broader availability of ART in combination with the establishment of care and treatment centres as part of the Tanzania National HIV/AIDS control program and (ii) the new approaches to handle prophylactically and therapeutically opportunistic infections also outside the Tanzania National HIV/AIDS control program.

The level of incorrect WHO clinical staging found in this study is almost similar to Ugandan experiences where about 50% of patients were inappropriately staged \[[@R20]\]. In routine clinical practice WHO clinical stages determine the direction of HIV/AIDS case management. Patients in clinical stages I and II usually receive long time appointments accompanied by minimum laboratory investigations. While, patients in clinical stages III and IV usually receive clinical and laboratory assessment to determine their eligibility to start ART. Therefore, when a sizable proportion of patients cannot be staged correctly at first contact in ART clinics, the initiation of ART is delayed and higher mortality rates can be expected in the first three months of ART \[[@R13]\].

More than half of our patients were in WHO clinical stages III and IV which was consistent to the number of patients with CD4 cell counts of less than 200 cells per µL. This is the reality of late presentation and a challenge to ART programs. Using the cut off point for severe immunosuppression of CD4 cell counts ≤200 cells per µL; comparison is more conservative based on the Tanzania Care and Treatment Guidelines \[[@R16]\]. However, if a CD4 cell count of ≤350 cells per µL is taken as cut off for advanced immune depression, then the proportion of patients with severe immune depression reaches about 70% of all cases seen in this study. Taking into consideration the high proportion of patients presenting late with obscured clinical features to care and treatment for the first time, it appears advantageous to classify patients into severe and moderate immune-suppression. Such an approach simplifies the process of clinical staging and reduces the chances of missed appropriate staging and hence delays in starting ART can be avoided.

In our study, skin diseases and fungal infections of the skin and mucous membranes indicated severe immuno-suppression when used clinically to stage patients. However, these symptoms do not strongly predict severe immunodeficiency based on CD4 decline (odds ratio 1.2, 95%CI, 0.52-2.92). In addition about 75% of patients with herpes zoster were severely immunosuppressed. Most of the symptoms showed high sensitivity in predicting severe immunosuppression which is also an indication of clinicians' adherence to treatment guidelines. When compared to CD4 count levels, there was no consistency. If the combination of three clinical features is used, the probability of predicting severe disease reaches 100% and is consistent with the decline of CD4 cell counts. High sensitivity with lower specificity further supports this patients' classification because of the vulnerability of HIV patients to opportunistic infections if missed and delayed to receive ART.

Based on these study findings, we then recommend for the local application of the new classification of HIV infected patients into severe and moderate immuno-suppression based on duration of clinical manifestations. This classification guided by local clinical experience - requires further validation. We recognize the small sample size used in this study as a limitation. However the composition of patients from rural and urban settings implies that the guidelines established can be used at a regional level. Therefore and besides our current own efforts, more studies should be conducted to validate the proposed approach of staging, not only for patients' classification but also for monitoring drug side effects and treatment failure in other geographical and endemic settings.

CONCLUSION
==========

The broader availability of HIV/AIDS treatment as well as new approaches to deal with opportunistic infections, we call for a review of the clinical presentations seen within care and treatment programs in different settings. Besides applying the WHO clinical staging care and treatment centres that look after large cohorts of HIV and AIDS patients information should also be collected to develop and validate site specific guidelines based on local experiences as shown in this study of which the results are currently being validated in other settings.
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###### 

Demographic and Clinical Characteristics of Patients at First Clinical Assessment Grouped by CD4 Cell Count Categories

  Variable                            All Patients (N=331)   CD4\>200 Cells per µL (N=140)   CD4≤200 Cells per µL (N=191)   p-Value
  ----------------------------------- ---------------------- ------------------------------- ------------------------------ ------------
  Median age in years(IQR)            36(12)                 36 (14)                         36 (10)                        
                                                                                                                            
  **Sex N (%)**                                                                                                             
  Male                                117(35.3)              49 (35.0)                       68 (35.6)                      *P=0.910*
  Female                              214(64.7)              91 (65.0)                       123 (64.4)                     
                                                                                                                            
  **Residential status N (%)**                                                                                              
  Urban                               108(32.6)              47 (33.6)                       61 (31.9)                      *P=0.754*
  Rural                               223(67.4)              93 (66.4)                       130 (68.1)                     
                                                                                                                            
  **WHO Clinical stage N (%)**                                                                                              
  I                                   59(17.8)               42 (30.0)                       17 (8.9)                       *P=0.0001*
  II                                  75(22.7)               38 (27.1)                       37 (19.4)                      
  III                                 95(28.7)               35 (25.0)                       60 (31.4)                      
  IV                                  102(30.8)              25 (17.9)                       77 (40.3)                      
                                                                                                                            
  Median CD4+ T- cells per µL (IQR)   158(253)               377 (259)                       77.5 (99.5)                    

###### 

Symptoms and Signs for HIV/AIDS Persisting for More than Two Weeks and their Performance to Predict severe Immunosuppression at First Assessment (P-value ≤ 0.25)

  Symptom/Sign                                   Frequency of Signs and Symptoms N (%)   CD4≤200 Cells per µL   WHO Clinical Stage III /IV   Sensitivity (%)   Specificity (%)        
  ---------------------------------------------- --------------------------------------- ---------------------- ---------------------------- ----------------- ----------------- ---- ----
  Weight loss \>5kg                              160 (48.3)                              1.39                   0.89-2.16                    2.49              1.58-3.95         81   46
  Cough                                          135 (40.8)                              1.44                   0.92-2.25                    3.28              2.02-5.32         82   36
  Fever                                          132 (39.9)                              1.67                   1.06-2.63                    2.74              1.70-4.41         83   43
  Headache                                       105 (31.7)                              0.96                   0.60-1.54                    1.22              0.76-1.97         80   60
  Dizziness                                      70 (21.1)                               1.53                   0.88-2.65                    1.93              1.06-3.43         80   46
  Peripheral neuropathy                          57 (17.2)                               1.00                   0.56-1.79                    1.44              0.79-2.63         85   58
  Diarrhoea                                      35 (10.6)                               1.95                   0.95-4.22                    1.55              0.73-3.28         84   70
  Skin diseases                                  34 (10.3)                               1.20                   0.58-2.50                    1.27              0.60-2.67         71   46
  Fungal infection (skin and mucous membranes)   24 (7.3)                                1.24                   0.52-2.92                    2.75              1.00-7.56         93   44

###### 

Performance of a Combination of Two Clinical Features in Predicting Severe Immunosuppression (P-value ≤ 0.25)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symptom/Signs\              Frequency of Signs and Symptoms N (%)   CD4≤200 Cells per µL   WHO Clinical Stages\   Sensitivity (%)   Specificity (%)        
  Combinations                                                                               III /IV                                                         
  --------------------------- --------------------------------------- ---------------------- ---------------------- ----------------- ----------------- ---- ----
  Cough and fever             74 (22.4)                               1.71                   0.99-2.95              3.39              1.82-6.28         84   29

  Weight loss and cough       84 (25.4)                               1.78                   1.06-2.99              3.79              2.11-6.81         86   32

  Cough and Diarrhoea         18 (5.4)                                1.97                   0.68-5.66              2.48              0.8-7.72          92   60

  Weight loss and fever       96 (29.0)                               1.40                   0.86-2.29              2.64              1.55-4.47         85   43

  Fever and diarrhoea         24 (7.3)                                2.32                   0.89-6.01              2.14              0.82-5.55         83   50

  Weight loss and diarrhoea   24 (7.3)                                1.85                   0.74-4.60              2.14              0.82-5.55         88   57

  Dizziness and diarrhoea     13 (3.9)                                4.21                   0.91-19.33             3.90              0.85-17.90        85   43
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Performance of a Combination of Three Clinical Features in Predicting Severe Immunosuppression (P-value ≤ 0.25)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symptom/Signs\                                        Frequency of Symptoms and Signs N (%)   CD4≤200 Cells per µL   WHO Clinical Stage III/IV          
  Combinations                                                                                                                                            
  ----------------------------------------------------- --------------------------------------- ---------------------- --------------------------- ------ ---------------
  Cough, fever, Weight loss\>5kg                        61(18.4)                                1.79                   0.99 -3.25                  3.80   1.89 - 7.62

  Cough, diarrhoea, difficult breathing                 10 (3.0)                                3.01                   0.63 - 14.42                6.36   0.79 - 50.85

  Fever, headache, diarrhoea                            13(3.9)                                 4.21                   0.92 - 19.33                3.90   0.85 - 17.90

  Fever, diarrhoea, Difficult breathing                 12(3.6)                                 2.25                   0.60 - 8.49                 3.52   0.763 - 16.37

  Weight loss\>5kg, headache, diarrhoea                 13(3.9)                                 4.21                   0.92 - 19.33                3.90   0.85 - 17.90

  Weight loss\>5kg, Difficult breathing poor appetite   38(11.5)                                1.68                   0.82 - 3.45                 5.19   1.97 - 13.67

  Abdominal pain, Headache, diarrhoea                   13(3.9)                                 2.52                   0.68 - 9.34                 2.33   0.63 - 8.64

  Headache, Difficult breathing, poor appetite          21(6.3)                                 1.90                   0.72 - 5.03                 3.06   1.00 - 9.33
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
